Stereotaxis completes Robocath acquisition

Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular intervention, announced on July 9, 2026, that it has completed its acquisition of Robocath, an innovator of robotic technologies for interventional cardiology and neurointerventions. The acquisition, previously announced in April 2026, was valued at approximately $20 million in cash and common stock. Robocath will be fully integrated into Stereotaxis, combining complementary technologies to accelerate development of next-generation robotic solutions for electrophysiology, interventional cardiology, and neurointerventions. The combined platform strengthens Stereotaxis's position as a leader in endovascular robotics. Robocath's R-One technology has demonstrated 98% technical procedure success with no major adverse cardiovascular events and has received CE and NMPA certifications. The acquisition is expected to provide commercial synergies and expand Stereotaxis's addressable market.